Maneesh Paul-Satyaseela, PhD, is the project leader and co-inventor of enmetazobactam at Orchid Pharma in India, which was recently approved by the European Medicines Agency, the U.S. Food and Drug Administration and the U.K. Medicines & Healthcare products Regulatory Agency for marketing in 2024 by out-licensing to Allecra Therapeutics GmbH. Dr. Paul-Satyaseela is a clinical microbiologist who has pursued basic and applied research discovering novel anti-infectives and characterizing several microbial genes and proteins. He led the anti-infectives discovery research group at Orchid Pharma and co-invented several preclinical candidates in antibacterial and antifungal space. He is the CEO of Microvioma, a company focussed on reimagining life by contributing to One Health by addressing the microbiota. He has translated scientific accomplishments and leadership through patents and publications. He received his master’s and doctoral degrees in medical microbiology in India (MAHE & Gulbarga University). As a postdoctoral fellow, he further trained in infectious diseases, specifically in the molecular mechanisms of the pathogenesis of neonatal microbial meningitis at Johns Hopkins University School of Medicine as well as the role of A. actinomycetemcomitans in the pathogenesis of atherosclerosis at Umeå University in Sweden. He was also the ORISE Fellow at the Center for Biologics Evaluation and Research at FDA, where he worked on reverse vaccinology for N. meningitidis.